C. Garrido

发表

Improvement in the determination of HIV‐1 tropism using the V3 gene sequence and a combination of bioinformatic tools

Natalia Chueca, Federico García, E. Poveda, 2009, Journal of medical virology.

Gold nanoparticles to improve HIV drug delivery.

D. Margolis, Daniel. C. Whitehead, Jamee Bresee, 2015, Future medicinal chemistry.

Improved Killing of HIV-infected Cells Using Three Neutralizing and Non-neutralizing Antibodies.

B. Haynes, D. Montefiori, D. Margolis, 2020, The Journal of clinical investigation.

Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo

D. Margolis, G. Ferrari, J. Pollara, 2018, Journal of Virology.

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function

J. Karn, A. Spivak, D. Margolis, 2016, Front. Immunol..

Resistance to integrase inhibitors.

V. Soriano, C. de Mendoza, C. Garrido, 2007, Journal of HIV therapy.

Raltegravir and etravirine are active against HIV type 1 group O.

E. Poveda, V. Soriano, V. Briz, 2009, AIDS research and human retroviruses.

Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters

E. Poveda, V. Soriano, L. Stuyver, 2008, Journal of Acquired Immune Deficiency Syndromes.

Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania.

L. Sandvik, S. G. Gundersen, A. Johannessen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure

G. Fouda, B. Yagnik, R. Amara, 2022, Frontiers in Immunology.

Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests

V. Soriano, C. de Mendoza, A. Corral, 2009, Journal of Clinical Microbiology.

Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola.

F. Antunes, V. Soriano, C. de Mendoza, 2008, The Journal of antimicrobial chemotherapy.

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

V. Soriano, E. Ribera, C. de Mendoza, 2012, AIDS research and human retroviruses.

Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay

N. Parkin, V. Soriano, C. de Mendoza, 2011, Journal of Clinical Microbiology.

Role of atazanavir in the treatment of HIV infection

V. Soriano, S. Rodríguez-Nóvoa, C. Garrido, 2008, Therapeutics and clinical risk management.

Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance.

W. Heneine, C. de Mendoza, A. Corral, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4°C

C. de Mendoza, N. Zahonero, C. Garrido, 2008, The Journal of antimicrobial chemotherapy.

Different disease progression rate according to HIV-1 subtype

C. Garrido, C. Mendoza, 2008 .

Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir

J. Benito, V. Soriano, C. de Mendoza, 2012, AIDS.

High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients

W. Heneine, C. de Mendoza, A. Corral, 2007, AIDS.

Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance

V. Soriano, C. de Mendoza, A. Corral, 2008, AIDS.

Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

C. Cruz, S. Lam, C. Rooney, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Dam-Infant Rhesus Macaque Pairs to Dissect Age-Dependent Responses to SARS-CoV-2 Infection.

K. V. Van Rompay, S. Permar, Jennifer Watanabe, 2022, ImmunoHorizons.

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

D. Margolis, N. Archin, David M. Margolis, 2014, Nature Reviews Microbiology.

SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques

Alan D. Curtis, M. Hudgens, D. Montefiori, 2021, Science Immunology.

SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques

Alan D. Curtis, M. Hudgens, D. Montefiori, 2021, Science Immunology.

Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers.

D. Margolis, David M Margolis, Carolina Garrido, 2017, Virus research.

Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis.

J. Tappero, M. Rodriguez‐Barradas, P. Leboit, 1997, The New England journal of medicine.

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.

V. Soriano, A. Geretti, C. de Mendoza, 2010, The Journal of antimicrobial chemotherapy.

Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.

E. Poveda, V. Soriano, C. de Mendoza, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients.

V. Soriano, C. de Mendoza, A. Corral, 2007, AIDS research and human retroviruses.

γδ T cells: an immunotherapeutic approach for HIV cure strategies.

M. Hudgens, D. Margolis, C. Garrido, 2018, JCI insight.

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

B. Rodés, C. Toro, V. Soriano, 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

HIV‐1 infection remains incurable owing to the pres‐ ence of quiescent, replication‐competent provirus within a long‐lived population of memory T cells, which are capable of reigniting new rounds of infection if therapy

D. Margolis, N. Archin, C. Garrido, 2014 .

Multi-omics analyses reveal that HIV-1 alters CD4 T cell immunometabolism to fuel virus replication

Xian Chen, M. Robb, R. Sékaly, 2021, Nature Immunology.

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection

D. Margolis, N. Archin, C. Garrido, 2015, PLoS pathogens.

Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents

C. Woods, C. Lorang, T. Burke, 2021, medRxiv.

Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1

M. Hudgens, J. Parker, S. Selitsky, 2023, bioRxiv.

Antiviral effect of raltegravir on HTLV-1 carriers.

V. Soriano, C. de Mendoza, T. Bar-Magen, 2012, The Journal of antimicrobial chemotherapy.

Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later

M. Hudgens, D. Montefiori, B. Graham, 2022, Science Translational Medicine.

Translational challenges in targeting latent HIV infection and the CNS reservoir problem

D. Margolis, C. Garrido, 2014, Journal of NeuroVirology.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

H. Liao, B. Haynes, D. Montefiori, 2015, The Journal of clinical investigation.

Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes

Natalia Chueca, E. Poveda, V. Soriano, 2008, Journal of Clinical Microbiology.

Distinct upper airway epithelium interferon-stimulated and profibrotic gene expression between adult and infant rhesus macaques infected with SARS-CoV-2

K. V. Van Rompay, S. Permar, Jennifer Watanabe, 2022, bioRxiv.

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

D. Margolis, N. Archin, M. Tolstrup, 2019, AIDS.

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

S. Lam, C. Rooney, C. Bollard, 2015, The Journal of infectious diseases.

High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.

E. Poveda, V. Soriano, E. Seclén, 2010, The Journal of antimicrobial chemotherapy.

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

V. Soriano, A. Geretti, C. de Mendoza, 2011, Antiviral research.

International Conference on Bartonella as emerging pathogens

D. Raoult, R. Zbinden, J. Tappero, 1999 .

Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation

M. Robb, N. Michael, R. Geleziunas, 2020, PLoS pathogens.

Translational challenges in targeting latent HIV infection and the CNS reservoir problem

D. Margolis, C. Garrido, 2015, Journal of NeuroVirology.

New therapeutic strategies for raltegravir.

V. Soriano, C. de Mendoza, C. Garrido, 2010, The Journal of antimicrobial chemotherapy.

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

M. Hudgens, D. Margolis, R. Gorelick, 2020, Scientific Reports.

Europe and Asia

E. Poveda, V. Soriano, C. de Mendoza, 2022 .

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens

V. Soriano, J. Villacian, T. Pattery, 2012, Antimicrobial Agents and Chemotherapy.

HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System

A. Johannessen, C. de Mendoza, N. Zahonero, 2010, The Journal of antimicrobial chemotherapy.

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

M. Hudgens, D. Margolis, R. Gorelick, 2020, Scientific Reports.

Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain.

E. Poveda, V. Soriano, C. de Mendoza, 2009, AIDS research and human retroviruses.

Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.

E. Poveda, V. Soriano, C. de Mendoza, 2008, Clinical Infectious Diseases.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

D. Montefiori, P. Moore, N. Archin, 2015, The Journal of clinical investigation.

Editorial: Immunotherapies Towards HIV Cure

A. Bosque, C. Garrido, M. Salgado, 2021, Frontiers in Cellular and Infection Microbiology.

Do integrase inhibitors impact on the HIV reservoir.

C. de Mendoza, C. Garrido, 2010, AIDS Reviews.

Raltegravir and etravirine are active against HIV type 1 group O.

E. Poveda, V. Soriano, V. Briz, 2009, AIDS research and human retroviruses.